Unknown

Dataset Information

0

Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice.


ABSTRACT: BACKGROUND AND PURPOSE:Recently, metformin, a well-known anti-diabetic drug, has been shown to possess anti-inflammatory activities. This study investigated the effect of metformin on the expression of pro-inflammatory cytokines including high mobility group box 1 (HMGB1) in lipopolysaccharide (LPS)-treated animals and cells. EXPERIMENTAL APPROACH:We investigated whether metformin inhibits the release of HMGB1 in LPS-treated RAW 264.7 cells and increases survival rate in endotoxaemic mice (lethal endotoxaemia was induced by an i.p. injection of LPS). This was achieved by a range of techniques including Western blotting, enzyme-linked immunosorbent assay, specific pharmacological inhibitors, knock out of ?(1) -subunit of AMP-activated protein kinase (AMPK) and recombinant HMGB1. KEY RESULTS:Both pre- and post-treatment with metformin significantly improved survival of animals during lethal endotoxaemia (survival rate was monitored up to 2 weeks), decreased serum levels of tumour necrosis factor-alpha (TNF-?), interleukin-1?, HMGB1 expression and myeloperoxidase activity in lungs. However, metformin failed to improve survival in endotoxaemic animals that had additionally been treated with recombinant HMGB1. In an in vitro study, metformin dose-dependently inhibited production of pro-inflammatory cytokines and HMGB1 release. Metformin activated AMPK by its phosphorylation. Compound C (pharmacological inhibitor of AMPK) and siAMPK?1 reversed the anti-inflammatory effect of metformin in LPS-treated cells. CONCLUSIONS AND IMPLICATIONS:Our data indicate that metformin significantly attenuates the pro-inflammatory response induced by LPS both in vivo and in vitro. Metformin improved survival in a mouse model of lethal endotoxaemia by inhibiting HMGB1 release. AMPK activation was implicated as one of the mechanisms contributing to this inhibition of HMGB1 secretion.

SUBMITTER: Tsoyi K 

PROVIDER: S-EPMC3057288 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice.

Tsoyi Konstantin K   Jang Hwa Jin HJ   Nizamutdinova Irina Tsoy IT   Kim Young Min YM   Lee Young Soo YS   Kim Hye Jung HJ   Seo Han Geuk HG   Lee Jae Heun JH   Chang Ki Churl KC  

British journal of pharmacology 20110401 7


<h4>Background and purpose</h4>Recently, metformin, a well-known anti-diabetic drug, has been shown to possess anti-inflammatory activities. This study investigated the effect of metformin on the expression of pro-inflammatory cytokines including high mobility group box 1 (HMGB1) in lipopolysaccharide (LPS)-treated animals and cells.<h4>Experimental approach</h4>We investigated whether metformin inhibits the release of HMGB1 in LPS-treated RAW 264.7 cells and increases survival rate in endotoxae  ...[more]

Similar Datasets

2016-02-25 | GSE76562 | GEO
2016-02-25 | E-GEOD-76562 | biostudies-arrayexpress
2006-06-06 | GSE4964 | GEO
2006-06-06 | GSE4962 | GEO
| S-EPMC3819897 | biostudies-literature
| S-EPMC4882984 | biostudies-literature
| S-EPMC9817878 | biostudies-literature
| S-EPMC2743705 | biostudies-literature
| S-EPMC4383338 | biostudies-literature
| S-EPMC6934980 | biostudies-literature